

Lorianne Masuoka K.
 Form 3
 December 04, 2009

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Â Lorianne Masuoka K. (Last) (First) (Middle)	2. Date of Event Requiring Statement (Month/Day/Year) 11/30/2009	3. Issuer Name and Ticker or Trading Symbol NEKTAR THERAPEUTICS [NKTR]	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below) SVP & Chief Medical Officer	5. If Amendment, Date Original Filed(Month/Day/Year)
---	--	---	---	--

C/O NEKTAR THERAPEUTICS,Â 201 INDUSTRIAL ROAD
 (Street)

SAN CARLOS,Â CAÂ 94070
 (City) (State) (Zip)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
------------------------------------	--	---	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable Expiration Date	Title Amount or Number of			

Edgar Filing: Lorianne Masuoka K. - Form 3

				Shares		or Indirect (I) (Instr. 5)	
Stock Option	Â (1)	08/28/2016	Common Stock	180,000	\$ 3.97	D	Â
Stock Option	Â (1)	02/23/2017	Common Stock	40,000	\$ 4.65	D	Â
Stock Option	Â (2)	02/23/2017	Common Stock	60,000	\$ 4.65	D	Â
Stock Option	Â (1)	06/16/2017	Common Stock	100,000	\$ 5.91	D	Â
Stock Option	Â (2)	11/23/2017	Common stock	160,000	\$ 8.76	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Lorianne Masuoka K. C/O NEKTAR THERAPEUTICS 201 INDUSTRIAL ROAD SAN CARLOS, CA 94070	Â	Â	Â SVP & Chief Medical Officer	Â

Signatures

Gil M. Labrucherie -
Attorney-in-Fact

12/04/2009

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 25% of the shares subject to the stock option vest on the one year anniversary of the grant date and the remainder of the shares vest pro-rata on a monthly basis over the following three years.
- (2) The shares subject to the stock option vest pro-rata on a monthly basis over four years from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.